和誉-B(02256.HK)：在第37届AACR-NCI-EORTC大会公布新型CDK4/2抑制剂和SMARCA2 PROTAC降解剂临床前研究成果
ABBISKOABBISKO(HK:02256) Ge Long Hui·2025-10-27 00:08

Core Viewpoint - The company announced the presentation of two pipeline projects, CDK4/2 inhibitor ABK-CDK-1 and SMARCA2 PROTAC degrader ABK-SM2-1, at the 37th AACR-NCI-EORTC International Molecular Targets and Cancer Therapeutics Conference, showcasing promising preclinical results [1]. Group 1 - The company has revealed the latest preclinical research results for two drug candidates [1]. - Both ABK-CDK-1 and ABK-SM2-1 demonstrated excellent preclinical characteristics [1].